|
Apr 16
|
Q1 2025 Johnson & Johnson Earnings Call
|
|
Apr 15
|
Stocks fizzle after two-day rally driven by bank earnings and tech
|
|
Apr 15
|
These Stocks Moved the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More
|
|
Apr 15
|
J&J expects a $400M hit from tariffs, mostly from China
|
|
Apr 15
|
J&J Forecasts $400 Million in Tariff-Related Costs This Year
|
|
Apr 15
|
Johnson & Johnson (JNJ): Stuck in a Range but Ready to Break Out if Legal Clouds Clear – Jim Cramer Weighs In
|
|
Apr 15
|
J&J projects $400m tariff hit but raises sales outlook
|
|
Apr 15
|
Equities Little Changed Intraday After Corporate Earnings
|
|
Feb 17
|
Why Johnson & Johnson (JNJ) Is One of the Best Drug Stocks to Buy Now
|
|
Feb 15
|
Dividend Investor With $1.05 Million In Stocks And $36,600 Annual Payout Shares Portfolio – 'Could These Picks Set You Up for Life?'
|
|
Feb 15
|
Johnson & Johnson (JNJ): Among the Best Forever Stocks to Buy Right Now
|
|
Feb 14
|
ROKU Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
|
|
Feb 14
|
Jim Cramer on Johnson & Johnson (JNJ): ‘Too Slow Growing’
|
|
Feb 14
|
J&J’s High Hopes for Heart-Rhythm Device Grounded by Safety Concerns
|
|
Feb 13
|
Johnson & Johnson (NYSE:JNJ) Goes Ex-Dividend Soon
|
|
Feb 13
|
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
|
|
Feb 13
|
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
|
|
Feb 13
|
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
|
|
Feb 13
|
Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead
|
|
Feb 13
|
Sanofi to take $250M charge on study failure for E. coli vaccine
|